Annovis Bio
ANVSAnnovis Bio is a late-stage clinical biotechnology company developing a drug platform to treat neurodegeneration by targeting multiple neurotoxic proteins simultaneously.
Table of contents
Earnings
Next report
Aug 11, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Annovis Bio is a late-stage clinical biotechnology company developing a drug platform to treat neurodegeneration by targeting multiple neurotoxic proteins simultaneously. The company's lead candidate, buntanetap, is designed to restore axonal transport and synaptic activity in patients with Alzheimer’s and Parkinson’s diseases. Their approach focuses on inhibiting the translation of toxic proteins like amyloid-beta, tau, and alpha-synuclein to reverse the toxic cascade leading to nerve cell death.
Annovis Bio distinguishes itself as a unique developer of multi-protein translation inhibitors that address the underlying mechanisms of neurodegeneration rather than targeting a single protein.
Questions, answered.
- What is Annovis Bio's market cap?
- Annovis Bio (ANVS) has a market capitalization of $83.0M and trades on NYSE.
- Who are Annovis Bio's competitors?
- Annovis Bio's key competitors include Eli Lilly and Company, Biogen Inc., Anavex Life Sciences, and others. These companies compete in similar markets and product categories.
- Who does Annovis Bio partner with?
- Annovis Bio's notable partners include Alzheimer’s Disease Cooperative Study, National Institute of Health, U.S. Army.
- Where is Annovis Bio headquartered?
- Annovis Bio is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2020.